ARID4B and prostate carcinoma: Recently, a study using prostate-specific Arid4b knockout mouse models showed that ARID4B is essential for the initiation and progression of PTEN-deficient prostate cancer, suggesting the synthetic essentiality of ARID4B in prostate cancer carries PTEN deletion (Figure 5) [87].